FENNEC PHARMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

Research Triangle Park, NC, September 9, 2021 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that management will participate in three upcoming virtual investor conferences, including H.C. Wainwright 23rd Annual Global Investment […]

Read More…

FENNEC PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021  ~ ~ If Approved by the FDA, PEDMARKTM Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ~ Company Has Approximately $27 Million in Cash and Cash Equivalents ~ Research Triangle Park, […]

Read More…

FENNEC ANNOUNCES RESULTS OF ANNUAL MEETING

Research Triangle Park, NC — (GlobeNewswire) – June 29, 2021 – Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated May 14, 2021 for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders held […]

Read More…

FENNEC PHARMACEUTICALS ANNOUNCES AMENDMENT TO INCREASE EXISTING SENIOR DEBT FACILITY

Research Triangle Park, NC, June 24, 2021 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients with localized, non-metastatic solid tumors, today announced an amendment to its existing senior debt facility with […]

Read More…

FENNEC PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION RESUBMISSION FOR PEDMARKTM

~ Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 ~ ~ NDA Resubmission for PEDMARK for the Prevention of Cisplatin-Induced Ototoxicity for Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~ ~ If Approved by the FDA, PEDMARK Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing […]

Read More…

FENNEC PHARMACEUTICALS RESUBMITS NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR PEDMARKTM

~ If Approved by the FDA, PEDMARK Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ Research Triangle Park, NC, May 28, 2021 – Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company, today announced the resubmission of its New Drug Application (NDA) to the U.S. Food […]

Read More…

Fennec Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update

~ Fennec Remains on Track to Finalize and Resubmit the New Drug Application for PEDMARK™ to the U.S. Food and Drug Administration in the Second Quarter of 2021 ~ ~ Company Has Approximately $27 Million in Cash and No Outstanding Debt ~ RESEARCH TRIANGLE PARK, N.C., May 13, 2021 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; […]

Read More…

FENNEC ANNOUNCES FISCAL YEAR 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

~ Fennec is Working Closely with its Third-Party Drug Product Manufacturer to Finalize the New Drug Application (NDA) Resubmission for PEDMARK™ ~ ~ Resubmission of the NDA for PEDMARKTM is Planned for the Second Quarter of 2021 ~ ~ Company Has Approximately $30 Million in Cash and No Outstanding Debt ~ Research Triangle Park, NC, March 30, […]

Read More…

FENNEC PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

~ The Company Continues to Work with the FDA and Its Third-Party Drug Product Manufacturer to Fully Address CRL and Prepare NDA Resubmission for PEDMARKTM ~ ~ No Clinical Safety or Efficacy Issues Identified; No Additional Studies Required for PEDMARKTM ~ ~ The Company Has Approximately $33 Million in Cash and No Outstanding Debt ~ […]

Read More…

FENNEC ANNOUNCES ISSUANCE OF U.S. PATENT FOR PEDMARK™

Research Triangle Park, NC, September 21, 2020 – Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that the U.S. Patent and Trademark Office will issue U.S. Patent 10,792,363 […]

Read More…